July 24, 2024

The Global Human Immunoglobulin (pH4) for Intravenous Injection Market driven by Growing Prevalence of Primary Immunodeficiency Diseases

Human Immunoglobulin (pH4) for Intravenous Injection is a plasma derived medicine administered intravenously to provide immediate enhancement of a patient’s immune system. It contains concentrated immunoglobulin G (IgG) antibodies purified from plasma collected from thousands of healthy donors. The product is compatible for most patients and provides long-term protection against bacterial and viral infections for individuals with primary immunodeficiencies. It has a pH of 4.25 which provides increased stability and slower absorption rate from injection sites. The global market has seen increased adoption due to improving diagnosis and treatment rates for primary immunodeficiencies across developing nations.

The global Human Immunoglobulin (pH4) for Intravenous Injection Market is estimated to be valued at US$ 2,055.76 Mn in 2023 and is expected to exhibit a CAGR of 16.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The key trend in the human immunoglobulin market includes introduction of subcutaneous administration which provides ease of use over intravenous injections. Subcutaneous immunoglobulin has 95% bioavailability and can be self-administered at home settings. This has led to significant preference among patients. Another trend is development of highly purified immunoglobulin preparations with improved viral safety by incorporating steam heating and nanofiltration in manufacturing. This has increased product adoption in treatment of various autoimmune and inflammatory diseases in addition to primary immunodeficiencies.

Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as the human immunoglobulin (pH4) for intravenous injection market requires significant capital investments and regulatory approvals.

Bargaining power of buyers: The bargaining power of buyers is high due to the availability of alternative treatments and generic substitution.

Bargaining power of suppliers: The bargaining power of suppliers is moderate as there are a few established suppliers in this market.

Threat of new substitutes: The threat of new substitutes is moderate as there are few product alternatives available.

Competitive rivalry: Competition in the market is high as major players compete on the basis of product quality, price, and service.

Key Takeaways
The global human immunoglobulin (pH4) for intravenous injection market is expected to witness high growth over the forecast period of 2023 to 2030. North America is expected to dominate the market during the forecast period due to growing demand for intravenous immunoglobulin therapies.

Regional analysis: North America is expected to account for the largest share of the global human immunoglobulin (pH4) for intravenous injection market during the forecast period. This is attributed to higher adoption of advanced immunoglobulin therapies, rising prevalence of autoimmune and inflammatory diseases, and presence of major market players in the region.

Key players: Key players operating in the human immunoglobulin (pH4) for intravenous injection market are Major players operating in the point of care infectious disease diagnostics market include Danaher Corporation, Abbott Laboratories, Alcon Laboratories, Inc., Hoffman-La Roche Ltd., Becton, Dickinson, and Company, Trinity Biotech Plc, AccuBioTech Co., Ltd. and Cardinal Health, Inc.

*Note:

1.      Source: Coherent Market Insights, Public sources, Desk research
2.      We have leveraged AI tools to mine information and compile it